Editing Sly syndrome (section)

==Treatment==
[[Vestronidase alfa-vjbk]] (trade name Mepsevii), an enzyme replacement therapy which is a recombinant form of human β-glucuronidase, is approved by U.S. Food and Drug Administration for the treatment of Sly syndrome.<ref>{{Cite journal |last=McCafferty |first=EH |last2=Scott |first2=LJ |date=April 2019 |title=Vestronidase alfa: A review in mucopolysaccharidosis VII |journal=BioDrugs |volume=33 |issue=2 |pages=233–240 |doi=10.1007/s40259-019-00344-7 |pmc=6469592 |pmid=30848434 |doi-access=free}}</ref> [[Hematopoietic stem cell transplant]] (HSCT) has been used to treat other types of MPS diseases, but this is not yet available for MPS-VII. Animal experiments suggest that HSCT may be an effective treatment for MPS-VII in humans.<ref name="MPS_Society" />